Aster DM Healthcare gets NCLT nod for QCIL merger by FY27

NCLT clears a key step in the merger process

Aster DM Healthcare Ltd. informed stock exchanges that it has received a certified true copy of an order from the National Company Law Tribunal (NCLT) sanctioning a Scheme of Amalgamation. The disclosure was made through an NSE filing dated 24 June, after market hours. The order relates to the amalgamation of Quality Care India Ltd (QCIL) with Aster DM Healthcare.

The company’s update positions the NCLT approval as a formal regulatory clearance for the corporate restructuring. At the same time, the filing also highlights what is not yet known from the disclosure. It does not establish whether the amalgamation will proceed on the original terms, the implementation timeline, or the financial impact on consolidated operations.

What the company said in the exchange filing

In the filing, Aster DM Healthcare stated that the NCLT, Hyderabad Bench has approved the amalgamation scheme. The company added that the scheme will become effective after the certified order is filed with the Registrar of Companies and after other conditions are fulfilled.

It also stated that following effectiveness, QCIL will be dissolved without winding up. Aster DM Healthcare said it will notify stock exchanges regarding the effective date “in due course.” For investors, this means the NCLT order is an important milestone, but the final activation of the scheme depends on procedural and conditional steps that are still pending.

Shareholder vote: 96.68% in favour

The merger with Quality Care India Ltd received what the company described as “overwhelming shareholder approval,” with 96.68% of votes in favour. The company indicated the transaction is on track for completion in Q1 of FY2026-27.

In a separate line of commentary included in the provided material, the company said it was waiting for legal modalities, expected to be completed by Q1FY27. While these statements point to a targeted completion window, the filing itself indicates the effective date will be communicated later, once the final legal steps are completed.

What still needs to happen before the scheme becomes effective

Although the NCLT sanction is a major requirement in court-approved schemes, the company’s note is clear that effectiveness comes later. The scheme becomes effective upon filing the certified NCLT order with the Registrar of Companies and meeting other conditions.

This distinction matters for tracking milestones. Until the filing is completed and conditions are met, the merger is not yet effective. The company also noted that its filing does not establish whether the amalgamation will proceed on the original terms, the final timeline for implementation, or the impact on consolidated operations.

Meetings for shareholders and unsecured creditors (Feb–Mar 2026)

The provided information also references an “ASTERDM Company Mergers Announcement 2026” noting that NCLT Hyderabad approves the merger scheme between Aster DM Healthcare and Quality Care India, and that equity shareholders and unsecured creditors were to meet between Feb 27 and Mar 13, 2026.

This scheduling context is relevant because it ties into the procedural steps typically required in a tribunal-led amalgamation. However, the material provided does not include outcomes of creditor meetings beyond the shareholder voting percentage cited for the merger.

Stock, symbol, and market snapshot mentioned in the data

The material includes several market reference points around Aster DM Healthcare:

• NSE symbol: ASTERDM
• A listed price point of ₹625.15 as on 18-Feb-2026 13:38:02 IST
• A reference that the share price was ₹706.65 at close on 24 Oct 2025, down 1.72% from the previous close of ₹719.00
• Market capitalisation stated as ₹36,613 crore

These figures provide context around how the company is tracked in the market, but the provided content does not link the stated prices directly to the NCLT order announcement.

Key facts table

Other regulatory and corporate disclosures mentioned

Beyond the merger update, the provided material includes a regulatory note regarding mandatory borrowing through debt securities. It states that beginning FY2022, in the event of shortfall in mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by stock exchanges at the end of a two-year block period. It further notes that entities identified as “LC” must disclose, in their initial disclosure for a financial year, which stock exchange would receive the fine if a shortfall occurs.

The material also mentions a BSE disclosure that Aster DM Healthcare’s Board of Directors meeting was scheduled on 26/03/2026 to consider and approve declaration of an interim dividend for FY2025-26. The record date, if the interim dividend is declared, was stated as Friday, April 3, 2026.

Background: earlier demerger plan for GCC and India businesses

The provided content notes that in November 2023, Aster DM Healthcare announced a plan to separate its GCC and India businesses. It also states that the demerger was approved in January 2024.

This earlier restructuring context is relevant because it shows the company has been pursuing corporate structure changes across periods. However, the current filing discussed here focuses on the amalgamation process involving QCIL and the NCLT’s sanctioning order.

Market impact and what investors can track next

From the information provided, the immediate market-relevant takeaway is the completion of a major regulatory step: receipt of the certified true copy of the NCLT order sanctioning the amalgamation scheme. But the company also cautioned that the filing does not establish the final timeline, whether terms change, or the financial impact on consolidated operations.

As a result, investors looking for clarity will need to monitor subsequent exchange filings for (1) the effective date after ROC filing, and (2) any operational disclosures that explain how the merger affects consolidated operations once implemented.

Conclusion

Aster DM Healthcare’s receipt of the certified NCLT order from the Hyderabad Bench marks a formal clearance for its QCIL amalgamation scheme, with shareholder approval of 96.68% already disclosed. The company has said the scheme becomes effective only after ROC filing and other conditions are met, and it will update exchanges on the effective date in due course, with legal modalities expected to complete by Q1FY27.